Mechanisms of Drug Resistance 1

• 368 · PDF CDC20 drives acquired resistance to CDK4/6 inhibitors in estrogen receptor positive breast cancer Kamal Pandey, SM Nashir Udden, Jamsey Mathew, Prasanna G. Alluri
• 369 · PDF Elucidation of intratumoral heterogeneity using patient-derived lung cancer cell line Tomoko Funazo, Hiroaki Ozasa, Takahiro Tsuji, Kazutaka Hosoya, Yusuke Shima, Masahiro Ooi, Keiichiro Suminaga, Kentaro Hashimoto, Hiroshi Yoshida, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Toyohiro Hirai
• 370 · PDF Low physiological pH drives P300 mediated acetylation of PARP1 and promotes PARP inhibitor resistance Hao Nie, Wei Zhou, Kaixin Cheng, Dajiang Guo, Liping Liao, Xu Zhang, Chen Wang, Rafal Zielinski, Janardan N. Gavade, Shruthi Sriramkumar, Yiming Fang, Shuai Wu, Hsin-Yao Tang, Andrew V. Kossenkov, Yuan Qi, Jinsong Liu, Kang Le, Dorothea C. Gruber, Michael Soth, Miriam D. Post, Anil K. Sood, Stefanie Flückiger-Mangual, Timothy A. Yap, Benjamin G. Bitler, Rugang Zhang
• 371 · PDF Integrative analysis of capivasertib mediated AKT blockade with AR inhibition in mouse PTEN-deficient prostate cancer Marco A. De Velasco, Kazuko Sakai, Daiki Nakatsu, Takafumi Minami, Mamoru Hashimoto, Shingo Toyoda, Saizo Fujimoto, Kazuhiro Yoshimura, Simon T. Barry, Cath Eberlein, Claire Rooney, Kazuto Nishio, Hirotsugu Uemura, Kazutoshi Fujita
• 372 · PDF ARNT2 and AhR promote resistance to HIF2a inhibitor belzutifan Dongkook Min, Sunil Poudel, Robert Morris, Irene Mitsiades, Monica Perez, Eric Zaniewski, Toshi Shioda, Esther Rheinbay, Mo Motamedi, Wilhelm Haas, Othon Iliopoulos
• 373 Mitochondrial bioenergetics sustain ABCB1-driven temozolomide resistance in glioblastoma multiforme Ashutosh Shrivastava, Manendra Singh Tomar, Chirag Kulkarni, Sreyanko Sadhukhan, Priyanka Prajapati, Amit Lahiri, Naibedya Chattopadhyay
• 374 · PDF On-target WRN mutations drive resistance to WRN inhibitors in TA-repeat-expanded MSI cancers Gabriele Picco, Yanhua Rao, Angham Al Saedi, Samantha Walker, Shriram Bhosle, Yang Lee, Maria Garcia-Casado, Gilberto Valdes Garcia, Kieron May, Francesco Sassi, James P. Phelan, Philip Landis, Brian Jones, Diana Munoz, Jay Prakash Jain, Paul A. Barsanti, Joshua P. Taygerly, Michael P. DeMartino, Emanuel Gonçalves, Andrea Bertotti, Livio Trusolino, Michael A. White, Geeta Sharma, Matthew A. Coelho, Jonathan Houseley, Benjamin Schwartz, Mathew J. Garnett
• 377 · PDF Effects of aneuploidy associated RAD21 gain on therapeutic response to PARP inhibition in Ewing sarcoma and prostate cancer Chloe Springer, Elise DeArment, Ruoxi W. Wang, Thomas Janas, Xiaofeng A. Su
• 378 · PDF PGRMC1 induced lipid metabolic reprogramming leads to sorafenib resistance in hepatocellular carcinoma Poornima Devi Narayanan, Abigail Ramirez, Jazmin Lopez, Mahalakshmi Vijayaraghavan, Alfredo Roman, Kyle Nguyen, Mitchel Amador Rojo, Kariina Garcia, Kritika Soni, Grace Hua, Rajkumar Lakshmanaswamy, Ramadevi Subramani
• 379 · PDF Cysteine-driven drug inactivation undermines covalent drug efficacy and drives resistance Maximilian Kobiesa, Jennifer A. Brain, Kelli J. Che, Leah G. Rector, Abby C. Jurasin, Sita Kugel, Lucas B. Sullivan
• 380 · PDF Chromatin rewiring and transcriptional plasticity drive a distinct dual-resistant state in ovarian cancer Won-Young Choi, Rachel Perkins, Jisun Kang, Haoxiang Lyu, Matthew S. Jung, Xiaoya Hou, Wei Li, Junming Yue, Wenjing Zhang
• 381 · PDF beta-Hydroxybutyrate-mediated lysine butyrylation determines therapy response in liver cancer Minghe Zhang, Yunong Xie, Linglin Liu, Yimiao He, Carol Man Carol Tong
• 382 · PDF Exploring the role of LONP1 in lon-traditional mechanisms of glioblastoma resistance Shashi Jain, Dahlia A. Ordaz, Javier Lepe, Naomi Lomeli, James Pham, Bhaskar Das, Daniela A. Bota
• 383 Single-cell transcriptomic analysis of treatment-persistent residual disease in BRAF-mutant lung adenocarcinoma Constance Nicq, Etienne Vignaud, Alice Da Silva, Raphael Schneider, Geneviève De Souza, Ludovic Bigot, Aurélie Swalduz, Olivier Calvayrac, Pierre Saintigny, Luc Friboulet, Sandra Ortiz-Cuaran
• 385 A genome derived non coding reporter of dynamic cancer cell state Noha Shendy, Yang Zhang, Stephanie Nance, Ha Won Lee, Shivendra Singh, Yousef Khashana, Vernon Ebegboni, Estevez Prado Daniel, Mohammad Ali Mohammad Nezhady, K. Elaine Ritter, Anoop Kavirayani, Bensheng Ju, Grace McKay-Corkum, Qi Liu, Yiping Fan, Gang Wu, Jun Qi, John B. Easton, Anand G. Patel, JUN YANG, Taosheng Chen, Brian Abraham, Adam D. Durbin
• 386 · PDF Targeting the YBX1-SREBP2 axis to overcome drug resistance in hepatocellular carcinoma Veerababu Nagati, Yamile Abuchard Anaya, Miguel Salazar, Kaylee Renteria, Ricardo Pequeno Bracho, Manish K Tripathi
• 387 · PDF Precision combination therapy opportunities in colorectal cancer revealed by PDX drug screening Alexey Sorokin, Preeti Kanikarla Marie, Jay Saynonh, Christian Beke Onana, Fengqin Gao, Zhensheng Liu, Maya Ridinger, Scott Kopetz
• 388 · PDF DYRK1A-mediated quiescence establishes a therapeutically-resistant reservoir for glioblastoma recurrence Ameesha Paliwal, Kevin Faust, Okty Abbasi Borhani, Rifat S. Sajid, Evelyn R. Kamski-Hennekam, Ingrid Jin, Johnny L. McRae, Anzar Alvi, Parsa Babaei Zadeh, Dimitrios G. Oreopoulos, Lauren Omoto, Phedias Diamandis
• 389 · PDF GSDMB drives cGAS-STING-mediated immune evasion in HER2-amplified colorectal cancer Junyong Weng, Tianchen Xiong, Xinxiang Li, Ajay Goel
• 390 Single cell multiomics reveals evolutionary and epigenomic trajectories of PARP inhibitor resistance in BRCA mutant TNBC Wei Hong, Pavan Kumar, Faiza Baameur Hancock, Helen M. Piwnica-Worms, Mahinur Mattohti
• 391 · PDF TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC) Ismail M. Meraz, Renduo Song, Shuhong Wu, Yi Xu, Meng Feng, Lihui Gao, Chenghui Ren, Qi Wang, Jun Li, Mourad Majidi, Jing Wang, Mark Berger, Jack A. Roth
• 392 · PDF EMT-like reprogramming drives drug-tolerant persister cell plasticity in mantle cell lymphoma via ribosome biogenesis Wei Wang, Yang Liu, Heng-Huan Lee, Fangfang Yan, Yue Fei, Yijing Li, Chengtai Yu, Lin Tan, Lorenzi Phil, Qingsong Cai, Lei Nie, Michael Wang
• 393 · PDF Uncovering mechanisms of PARP inhibitor resistance in IDH1-mutant cancers via serial tumor transplantation and genome wide CRISPR-Cas9 knockout screen Daniel Andres Colon-Rios, Jonathan Dow, Adam Krysztofiak, Yanfeng Liu, Faye A. Rogers, Peter M. Glazer
• 394 · PDF Adaptive resistance mechanisms to mTOR inhibitor in lung squamous cell carcinoma Milica Momcilovic
• 395 · PDF Identification of drug resistance factors in ALK-rearranged lung cancer using genome-wide CRISPR activation screening Mai Nagasaka, Marie Kawahara, Ken Uchibori, Makoto Nishio, Ryohei Katayama
• 396 · PDF Nrf2 role in regulating kaempferol's inhibitory action on CDKs, PD-L-1, CCL2, and TGM2 in triple-negative breast cancer cells Sukhmandeep Kaur, Patricia Mendonca, Shubham D. Mishra, Karam F. a. Soliman

在完整检索应用中浏览本分会场 →